Screener
D&A at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by Guardian Pharmacy Services in its filing.
Tagged under the XBRL concept us-gaap:DepreciationDepletionAndAmortization.
The source filing: Guardian Pharmacy Services’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:17 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-338074
| (In thousands) | Six Months Ended June, 30 / 2025 | Six Months Ended June, 30 / 2026 |
|---|---|---|
| Operating activities | ||
| Net income | $18,100 | $35,665 |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||
| Depreciation and amortization | 10,756 | 11,784 |
| Share-based compensation expense | 8,414 | 4,793 |
| Provision for losses on accounts receivable | 1,904 | 2,844 |
| Other | 430 | 39 |
| Changes in operating assets and liabilities: |
ITEM 1. Financial Statements
FAQ
- What is Guardian Pharmacy Services's D&A?
- Guardian Pharmacy Services (GRDN) reported D&A of $5.81M in Q2 2026.
- How has Guardian Pharmacy Services's D&A changed year-over-year?
- Guardian Pharmacy Services's D&A increased by 5.8% year-over-year, from $5.49M to $5.81M.
- What does D&A mean?
- Total non-cash depreciation of tangible assets and amortization of intangible assets — the largest add-back to net income in the operating cash flow reconciliation.
Ask your AI about Guardian Pharmacy Services's d&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude